ATLAS News · Companies
The Globe and Mail reports Moderna issued a cost outlook amid revenue uncertainty, while The Motley Fool compares its losses with Axsome's growth.
The Globe and Mail reports that Moderna (MRNA) issued an outlook on its costs while the company faces uncertainty over its revenue. The outlet also notes that the stock fell.
The Motley Fool published a separate comparison of Axsome Therapeutics and Moderna. According to its description, Axsome's revenue has climbed about 54%, while Moderna's net losses run deep.
The Motley Fool also points to a steep valuation gap between the two biotech companies as a factor in its comparison.
Biotech companies often update investors on spending plans while their future sales remain hard to forecast.
The cost outlook and revenue uncertainty highlight the financial pressures Moderna is dealing with, which investors may weigh when assessing the company.
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
Healthcare · NASDAQ
live price · USD
Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.
ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy
ATLAS